Phase II open label study of valproic acid in spinal muscular atrophy

Kathryn J Swoboda, Charles B Scott, Sandra P Reyna, Thomas W Prior, Bernard LaSalle, Susan L Sorenson, Janine Wood, Gyula Acsadi, Thomas O Crawford, John T Kissel, Kristin J Krosschell, Guy D'Anjou, Mark B Bromberg, Mary K Schroth, Gary M Chan, Bakri Elsheikh, Louise R Simard, Kathryn J Swoboda, Charles B Scott, Sandra P Reyna, Thomas W Prior, Bernard LaSalle, Susan L Sorenson, Janine Wood, Gyula Acsadi, Thomas O Crawford, John T Kissel, Kristin J Krosschell, Guy D'Anjou, Mark B Bromberg, Mary K Schroth, Gary M Chan, Bakri Elsheikh, Louise R Simard

Abstract

Preliminary in vitro and in vivo studies with valproic acid (VPA) in cell lines and patients with spinal muscular atrophy (SMA) demonstrate increased expression of SMN, supporting the possibility of therapeutic benefit. We performed an open label trial of VPA in 42 subjects with SMA to assess safety and explore potential outcome measures to help guide design of future controlled clinical trials. Subjects included 2 SMA type I ages 2-3 years, 29 SMA type II ages 2-14 years and 11 type III ages 2-31 years, recruited from a natural history study. VPA was well-tolerated and without evident hepatotoxicity. Carnitine depletion was frequent and temporally associated with increased weakness in two subjects. Exploratory outcome measures included assessment of gross motor function via the modified Hammersmith Functional Motor Scale (MHFMS), electrophysiologic measures of innervation including maximum ulnar compound muscle action potential (CMAP) amplitudes and motor unit number estimation (MUNE), body composition and bone density via dual-energy X-ray absorptiometry (DEXA), and quantitative blood SMN mRNA levels. Clear decline in motor function occurred in several subjects in association with weight gain; mean fat mass increased without a corresponding increase in lean mass. We observed an increased mean score on the MHFMS scale in 27 subjects with SMA type II (p<or=0.001); however, significant improvement was almost entirely restricted to participants <5 years of age. Full length SMN levels were unchanged and Delta7SMN levels were significantly reduced for 2 of 3 treatment visits. In contrast, bone mineral density (p<or=0.0036) and maximum ulnar CMAP scores (p<or=0.0001) increased significantly.

Conclusions: While VPA appears safe and well-tolerated in this initial pilot trial, these data suggest that weight gain and carnitine depletion are likely to be significant confounding factors in clinical trials. This study highlights potential strengths and limitations of various candidate outcome measures and underscores the need for additional controlled clinical trials with VPA targeting more restricted cohorts of subjects.

Trial registration: ClinicalTrials.gov.

Trial registration: ClinicalTrials.gov NCT00374075.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Brahe C, Bertini E. Spinal muscular atrophies: recent insights and impact on molecular diagnosis. J Mol Med. 1996;74:555–562.
    1. Roberts DF, Chavez J, Court SD. The genetic component in child mortality. Arch Dis Child. 1970;45:33–38.
    1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. 1978;15:409–413.
    1. Czeizel A, Hamula J. A hungarian study on Werdnig-Hoffmann disease. J Med Genet. 1989;26:761–763.
    1. Emery AE. Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul Disord. 1991;1:19–29.
    1. Merlini L, Stagni SB, Marri E, Granata C. Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy. Neuromuscul Disord. 1992;2:197–200.
    1. Lefebvre S, Burgien L, Reboullet S, Clermont O, Burlet P, et al. Identification and Characterization of a Spinal Muscular Atrophy-determining Gene. Cell. 1995;80:155–165.
    1. Wan L, Battle DJ, Yong J, Gubitz AK, Kolb SJ, et al. The Survival of Motor Neurons Protein Determines the Capacity for snRNP Assembly: Biochemical Deficiency in Spinal Muscular Atrophy. Mol Cell Biol. 1995;25(13):5543–51.
    1. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1998;96:6307–6311.
    1. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular Atrophy. Am J Hum Genet. 2002;70(2):358–368.
    1. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, et al. Molecular Analysis of Spinal Muscular Atrophy and Modification of the Phenotype by SMN2. Genet Med. 2002;4:20–26.
    1. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57:704–712.
    1. Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422–428.
    1. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004;130:307–310.
    1. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265–269.
    1. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808–9813.
    1. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481–2489.
    1. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647–654.
    1. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004;12:59–65.
    1. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol. 2005;58:194–202.
    1. Brichta L, Holker I, Haug K, Klockgether T, Wirth B. In Vivo Activation of SMN in Spinal Muscular Atrophy Carriers and Patients Treated with Valproate. Ann Neurol. 2006;59:970–975.
    1. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2005;13:256–259.
    1. Kernochan LE, Russo ML, Woodling NS, Huynh TN, Avila AM, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet. 2005;14:1171–1182.
    1. Leng Y, Chuang DM. Endogenous α-Synuclein is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity. J Neurosci. 2006;26(28):7502–7512.
    1. van Bergeijk J, Haastert K, Grothe C, Claus P. Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein. Chem Biol Drug Des. 2006;67:244–247.
    1. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci. 2004;20:3179–3183.
    1. Petri S, Kiaei M, Kipiani K, Chen J, Chalingasan NY, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2006;22:40–49.
    1. Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis. 2006;24:286–295.
    1. Tsai LK, Tsai MS, Ting CH, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med. 2008;86:1243–1254.
    1. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscular atrophy. Neurology. 2006;67:500–501.
    1. Tsai LK, Yang CC, Hwu WL, Li H. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007;14:e8–e9.
    1. Main M, Kairon K, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155–159.
    1. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006;16:417–426.
    1. Mercuri E, Messina S, Battini R, Berrardinelli A, Boffi P, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a Multicentric Study. Neuromuscul Disord. 2006;16:93–98.
    1. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve. 2002;25:445–447.
    1. Simard LR, Belanger M-C, Morrissette S, Wride M, Prior TW, et al. Pre-clinical validation of a multiplex real-time RT-PCR assay to quantify SMN transcripts in whole blood from SMA patients. Neurology. 2007;68:451–456.
    1. Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, et al. SMN mRNA and protein levels in peripheral blood. Neurology. 2006;66:1067–1073.
    1. Melegh B, Pap M, Morava E, Molnar D, Dani M, et al. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr. 1994;125:317–321.
    1. Tein I, Sloane AE, Donner EJ, Lehotay DC, Millington DS, et al. Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr Neurol. 1995;12:21–30.
    1. Crawford TO, Sladky JT, Hurko O, Besner-Johnston A, Kelley RI. Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol. 1999;45:337–343.
    1. Coulter DL. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet. 1984;1(8378):689.
    1. Kumandas S, Koklu E, Gümüs H, Koklu S, Kurtoglu S, et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab. 2006;19:529–534.
    1. Boluk A, Guzelipek M, Savlı H, Temel I, Iın Ozıık H, et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 2004;50:93–97.
    1. Ecevit C, Aydoğan A, Kavakli T, Altinöz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol. 2004;31:279–282.
    1. Leet AI, Mesfin A, Pichard C, Launay F, Brintzenhofeszoc K, et al. Fractures in children with cerebral palsy. J Pediatr Orthop. 2006;26:624–627.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir